Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05999084 · ClinicalTrials.gov registry record
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
A clinical trial of Alzheimer Disease, sponsored by Emory University.
- Recruiting
- Registry status
- 735
- Enrollment target
- 8
- Study locations
NCT05999084 is a study of Alzheimer Disease that is actively recruiting participants, run by Emory University. The registered enrollment target is 735 participants, below the 2,748-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (73% lower). The trial reports 8 study locations across 1 state.
The verdict
NCT05999084, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- 735 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.
Conditions Studied
Interventions
- DRUG Anti-amyloid Monoclonal Antibodies (mAbs)
- COMBINATION_PRODUCT Standard of Care
Study Locations (8)
Georgia
- Georgia Memory Net Memory Assessment Clinic - Albany - Albany
- Georgia Memory Net Memory Assessment Clinic - Atlanta - Atlanta
- Emory Clinic - Atlanta
- Georgia Memory Net Memory Assessment Clinic - Augusta - Augusta
- Georgia Memory Net Memory Assessment Clinic - Gainesville - Gainesville
- Georgia Memory Net Memory Assessment Clinic - Macon - Macon
- Georgia Memory Net Memory Assessment Clinic - Savannah - Savannah
- Georgia Memory Net Memory Assessment Clinic - Vidalia - Vidalia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 735 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2028-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05999084
The ClinicalTrials.gov registry entry for NCT05999084 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 735 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (73% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Anti-amyloid Monoclonal Antibodies (mAbs) is the first listed.
NCT05999084 reports 8 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05999084 about?
NCT05999084 is a clinical study titled "Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry". The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.
What is the current status of trial NCT05999084?
This trial is currently recruiting. The enrollment target is 735 participants. The study started on 2025-03-06. Estimated completion is 2028-07.
What conditions does trial NCT05999084 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05999084?
The interventions under investigation include: Anti-amyloid Monoclonal Antibodies (mAbs) (DRUG), Standard of Care (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05999084?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05999084 being conducted?
This trial has 8 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.